ENGINEERED for the Scientific Race
Overview
Solve your most complex recombinant protein production needs
With over 22 years of experience, IPA specializes in delivering high-quality recombinant protein expression and purification, available as a standalone service or integrated into antibody discovery projects. Our dedicated team of protein scientists is committed to producing the protein tools you need, whether for pre-IND studies or as a component of your diagnostic kit.
High-quality meets efficiency to advance your research
IPA's advanced protein production workflows are customized to deliver a wide variety of conventional to complex recombinant proteins and antibody formats, including mono-, bi-, tri-, and multispecific antibodies, suitable for research and pre-clinical applications. Our efficient processes ensure accelerated turnaround times and exceptional results.
Cutting-edge technology and flexible solutions
Utilizing the rPEX® platform with HEK and CHO cell lines, we ensure the highest quality, scalability, and stability in our manufactured products. Additionally, we offer the flexibility to work with your stable cell lines and hybridomas, providing customized solutions to meet your specific requirements.
Services
Expert protein production services customized to your needs.
Transient Protein Production Platform (rPEx®)
IPA's proprietary rPEx® platform offers a cutting-edge solution for producing fully post-translationally modified recombinant proteins and antibodies. Utilizing serum-free, suspension-growing HEK and CHO cells, transiently transfected with our proprietary expression vectors containing your gene of interest. The rPEx platform delivers products in less then 7 weeks with high purity and quality, featuring endotoxin levels below 1.0 EU/mg, whether you need just a few hundred micrograms or up to gram amounts of purified antibody or protein.
Bi- and Multispecific Protein Production
With over two decades of expertise in recombinant protein production, IPA excels in delivering high-quality biomolecules. Our cutting-edge rPEx-ms platform, featuring innovative knob-in-hole or duobody technologies, is designed for the efficient production of bi- and multispecific recombinant antibodies. From high-throughput discovery programs (10 – 100 µg) to automated medium-scale production projects (100 µg – 10 mg) and large-scale preparative batch productions (10 mg – 1 gram), IPA provides tailored solutions to meet your needs. Achieve superior quality bispecific antibodies that drive your research and development projects forward.
Quality. Efficiency. Flexibility.
• > 95 % purity
• Low in endotoxin, < 1 EU/mg
• High success rate, > 99 %
• > 8500 Productions
• > 3000 Projects
• High client retention
Diverse Antibody Formats
• Full antibody
• VHH
• VNAR
• scFv
Species:
• Human
• Mouse
• Rabbit
• Llama
• Other
Isotype:
• IgG
• IgM
• IgA
• IgE
Specificity:
• Mono specific
• Bi-Specific
• Multi-specific
• Knob-in-hole
Versatile Protein Formats
Fusion protein:
• Fc
• GH
• MBP
• GST
Location:
• Secreted
• Intracellular
Tag:
• Untagged
• His
• Strep
• C-tag
• FLAG
Optional protease site:
• TEV
• Enterokinase
Fast turnaround, dedicated to quality, and optimized for maximum protein yields
Explore a solution crafted for you. With our innovative project strategy and unparalleled flexibility, we redefine excellence with a state-of-the-art lab in Europe shipping anywhere globally.
Trending topics
Lead the way with IPA.
Trending topics
We have the longest memory
Rabbit monoclonal antibodies with B Cell Select® with Function-First from IPA are unmatched for early identification of a high affinity, highly specific antibodies.
Bispecifics & IPA
Bring us your scaffold and we can do the rest. With years of experience using a variety of bi- and multi-specific modalities, IPA has end-to-end capabilities and throughput to ensure selection and development of the most relevant therapeutic candidates.
Wet lab + in silico
with LENSai
LENSai in silico applications for radically informed decisions are designed to lend great cost and time efficiencies, as part of the IPA antibody discovery portfolio of service.